Clinical Trials
Braintumor Website

 For People with Newly Diagnosed Glioblastoma Multiforme
A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM)
With Epidermal Growth Factor Receptor (EGFR) Amplification

 For People with Reccurent Glioblastoma Multiforme (and other malignant gliomas)
A Study of ABT-414 in Adult or Pediatric Subjects With Recurrent Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Glioblastoma at First Recurrence or Progression
Neuroblate MRI-Guided Laser Surgery for recurrent GBM.
Aldoxorubicin Trial for recurrent GBM.

These trials were the most recently added or updated

NCT Trial Name# of CentersLast Updated

NCT03090386

  Evaluation of Cognitive-Communication Deficits Following Treatment of Primary Brain Tumor Patients
103/23/2017

NCT03050268

  Familial Investigations of Childhood Cancer Predisposition
103/23/2017

NCT02993146

  Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
203/23/2017

NCT02858895

  Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Glioblastoma at First Recurrence or Progression
603/23/2017

NCT02589522

  VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
203/23/2017

NCT02481154

  Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
903/23/2017

NCT01817751

  Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients With Recurrent High-Grade Glioma
103/23/2017

NCT03018288

  Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
103/22/2017

NCT02423343

  A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioblastoma
1003/22/2017

NCT02133183

  Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma
503/22/2017

NCT01922076

  WEE1 Inhibitor AZD1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
1003/22/2017

NCT01851733

  MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme
103/22/2017

NCT02536339

  Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
1903/21/2017

NCT02374242

  Anti?PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases
403/21/2017

NCT01491893

  PVSRIPO for Recurrent Glioblastoma (GBM)
103/21/2017

NCT00001595

  An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
103/21/2017

NCT03068520

  Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease Progression?
103/20/2017

NCT01622868

  Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
10803/20/2017

NCT02525692

  Oral ONC201 in Adult Recurrent Glioblastoma
203/19/2017

NCT03089749

  Characterization of Human Autoantibody Titers After Central Nervous System Insult
103/17/2017

NCT02667587

  Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer).
11403/17/2017

NCT01849146

  WEE1 Inhibitor AZD1775, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma
103/17/2017

NCT02780804

  Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
1903/16/2017

NCT02685605

  Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
103/16/2017

NCT02639546

  iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors
2403/16/2017

NCT01843413

  Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases
103/16/2017

NCT02866747

  A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma
203/15/2017

NCT02764151

  First in Patient Study for PF-06840003 in Malignant Gliomas
1503/15/2017

NCT02709889

  Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
2103/15/2017

NCT02639325

  Tumor Related Epilepsy
103/15/2017

NCT02020720

  18F-DOPA-PET in Planning Surgery in Patients With Gliomas
103/15/2017

NCT01534104

  MRI and Diffusion Imaging of Eloquent Brain Areas to Optimize Brain Tumor Resection Planning
103/15/2017

NCT02864368

  Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens
103/14/2017

NCT02831959

  Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS)
2203/14/2017

NCT02650401

  Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
803/14/2017

NCT02546102

  Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
6403/14/2017

NCT03047473

  Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme
103/13/2017

NCT02968940

  Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma
103/13/2017

NCT02619864

  mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme
503/13/2017

NCT02526017

  Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers
3903/13/2017

NCT02095132

  WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
2003/13/2017

NCT02941536

  Correlation Between Circulating Tumor Cells and Brain Disease Control After Focal Radiotherapy for Metastases of Breast Cancer
103/12/2017

NCT01806675

  18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
103/12/2017

NCT03082144

  Concurrent Involved-field Radiotherapy and Intrathecal Chemotherapy for Leptomeningeal Metastases From Solid Tumors
103/10/2017

NCT03034135

  Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
103/10/2017

NCT02798406

  Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
603/10/2017

NCT02192359

  Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
103/10/2017

NCT02153957

  Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors
103/10/2017

NCT02101905

  Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
203/10/2017

NCT01538264

  Blood Flow MRI for Monitoring Brain Tumors
103/10/2017



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites